vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and FGI Industries Ltd. (FGI). Click either name above to swap in a different company.
FGI Industries Ltd. is the larger business by last-quarter revenue ($30.5M vs $18.7M, roughly 1.6× CytomX Therapeutics, Inc.). CytomX Therapeutics, Inc. runs the higher net margin — -0.8% vs -8.6%, a 7.8% gap on every dollar of revenue. On growth, FGI Industries Ltd. posted the faster year-over-year revenue change (-14.4% vs -25.7%). FGI Industries Ltd. produced more free cash flow last quarter ($2.3M vs $-15.8M). Over the past eight quarters, FGI Industries Ltd.'s revenue compounded faster (-0.5% CAGR vs -15.9%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
FGI Industries Ltd is a global designer, manufacturer and distributor of kitchen and bath products, home organization solutions, and home improvement goods. It serves major retail chains, home specialty stores and e-commerce platforms across North America, Europe and the Asia-Pacific region.
CTMX vs FGI — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $30.5M |
| Net Profit | $-154.0K | $-2.6M |
| Gross Margin | — | 26.7% |
| Operating Margin | -6.9% | -2.2% |
| Net Margin | -0.8% | -8.6% |
| Revenue YoY | -25.7% | -14.4% |
| Net Profit YoY | 97.6% | -553.1% |
| EPS (diluted) | — | $-1.63 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $30.5M | ||
| Q3 25 | — | $35.8M | ||
| Q2 25 | $18.7M | $31.0M | ||
| Q1 25 | $50.9M | $33.2M | ||
| Q4 24 | $38.1M | $35.6M | ||
| Q3 24 | $33.4M | $36.1M | ||
| Q2 24 | $25.1M | $29.4M | ||
| Q1 24 | $41.5M | $30.8M |
| Q4 25 | — | $-2.6M | ||
| Q3 25 | — | $-1.7M | ||
| Q2 25 | $-154.0K | $-1.2M | ||
| Q1 25 | $23.5M | $-629.1K | ||
| Q4 24 | $18.9M | $-402.3K | ||
| Q3 24 | $5.7M | $-550.1K | ||
| Q2 24 | $-6.5M | $163.6K | ||
| Q1 24 | $13.8M | $-412.2K |
| Q4 25 | — | 26.7% | ||
| Q3 25 | — | 26.5% | ||
| Q2 25 | — | 28.1% | ||
| Q1 25 | — | 26.8% | ||
| Q4 24 | — | 24.6% | ||
| Q3 24 | — | 25.8% | ||
| Q2 24 | — | 30.5% | ||
| Q1 24 | — | 27.4% |
| Q4 25 | — | -2.2% | ||
| Q3 25 | — | 1.0% | ||
| Q2 25 | -6.9% | -2.7% | ||
| Q1 25 | 44.4% | -3.9% | ||
| Q4 24 | 46.4% | -3.5% | ||
| Q3 24 | 12.3% | -0.2% | ||
| Q2 24 | -33.7% | -1.5% | ||
| Q1 24 | 28.1% | -1.0% |
| Q4 25 | — | -8.6% | ||
| Q3 25 | — | -4.6% | ||
| Q2 25 | -0.8% | -4.0% | ||
| Q1 25 | 46.2% | -1.9% | ||
| Q4 24 | 49.6% | -1.1% | ||
| Q3 24 | 17.2% | -1.5% | ||
| Q2 24 | -26.0% | 0.6% | ||
| Q1 24 | 33.3% | -1.3% |
| Q4 25 | — | $-1.63 | ||
| Q3 25 | — | $-0.86 | ||
| Q2 25 | — | $-0.64 | ||
| Q1 25 | — | $-0.07 | ||
| Q4 24 | — | $-0.38 | ||
| Q3 24 | — | $-0.29 | ||
| Q2 24 | — | $0.08 | ||
| Q1 24 | — | $-0.04 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | $1.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $119.9M | $17.3M |
| Total Assets | $175.1M | $69.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $1.9M | ||
| Q3 25 | — | $1.9M | ||
| Q2 25 | $49.0M | $2.5M | ||
| Q1 25 | $47.6M | $1.2M | ||
| Q4 24 | $38.1M | $4.6M | ||
| Q3 24 | $40.6M | $3.0M | ||
| Q2 24 | $43.2M | $1.3M | ||
| Q1 24 | $36.2M | $3.3M |
| Q4 25 | — | $17.3M | ||
| Q3 25 | — | $19.7M | ||
| Q2 25 | $119.9M | $21.3M | ||
| Q1 25 | $25.0M | $21.8M | ||
| Q4 24 | $-456.0K | $22.3M | ||
| Q3 24 | $-23.5M | $23.5M | ||
| Q2 24 | $-31.2M | $23.8M | ||
| Q1 24 | $-31.7M | $23.9M |
| Q4 25 | — | $69.5M | ||
| Q3 25 | — | $73.0M | ||
| Q2 25 | $175.1M | $71.7M | ||
| Q1 25 | $98.5M | $68.5M | ||
| Q4 24 | $120.5M | $75.5M | ||
| Q3 24 | $139.0M | $74.7M | ||
| Q2 24 | $159.2M | $69.9M | ||
| Q1 24 | $184.7M | $68.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $2.3M |
| Free Cash FlowOCF − Capex | $-15.8M | $2.3M |
| FCF MarginFCF / Revenue | -84.6% | 7.5% |
| Capex IntensityCapex / Revenue | 0.1% | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | $-212.5K |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $2.3M | ||
| Q3 25 | — | $-1.9M | ||
| Q2 25 | $-15.8M | $7.6M | ||
| Q1 25 | $-21.0M | $-7.4M | ||
| Q4 24 | $-19.9M | $617.4K | ||
| Q3 24 | $-20.7M | $-915.0K | ||
| Q2 24 | $-19.5M | $862.1K | ||
| Q1 24 | $-26.0M | $-8.0M |
| Q4 25 | — | $2.3M | ||
| Q3 25 | — | $-2.1M | ||
| Q2 25 | $-15.8M | $7.4M | ||
| Q1 25 | $-21.2M | $-7.7M | ||
| Q4 24 | $-20.0M | $-214.1K | ||
| Q3 24 | $-20.7M | $-1.1M | ||
| Q2 24 | $-19.6M | $281.5K | ||
| Q1 24 | $-26.2M | $-8.6M |
| Q4 25 | — | 7.5% | ||
| Q3 25 | — | -5.9% | ||
| Q2 25 | -84.6% | 23.8% | ||
| Q1 25 | -41.6% | -23.3% | ||
| Q4 24 | -52.5% | -0.6% | ||
| Q3 24 | -62.1% | -3.0% | ||
| Q2 24 | -78.2% | 1.0% | ||
| Q1 24 | -63.1% | -28.0% |
| Q4 25 | — | 0.2% | ||
| Q3 25 | — | 0.7% | ||
| Q2 25 | 0.1% | 0.7% | ||
| Q1 25 | 0.2% | 1.1% | ||
| Q4 24 | 0.2% | 2.3% | ||
| Q3 24 | 0.1% | 0.5% | ||
| Q2 24 | 0.4% | 2.0% | ||
| Q1 24 | 0.3% | 2.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.89× | — | ||
| Q4 24 | -1.05× | — | ||
| Q3 24 | -3.61× | — | ||
| Q2 24 | — | 5.27× | ||
| Q1 24 | -1.89× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
FGI
| Sanitaryware | $19.1M | 63% |
| Shower System | $5.8M | 19% |
| Kitchen And Bath Other | $3.3M | 11% |
| Bath Furniture Products | $2.3M | 7% |
